文献速递瓣膜外科

2016年STS/ACC经导管瓣膜治疗登记年度报告

2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.
PubMed 文献 · Ann Thorac Surg · 2016-12-09

该报告基于STS/ACC TVT登记,回顾2012年至2015年底美国所有商用经导管瓣膜装置患者数据。经导管主动脉瓣置换患者预估30天手术死亡风险从7%降至6%,TVT PROM从4%降至3%,住院死亡率从5.7%降至2.9%,1年死亡率从25.8%降至21.6%,但30天起搏器植入率从2013年8.8%升至2015年12.0%。二尖瓣夹合患者院内死亡率2%,87%患者二尖瓣反流降至≤2级;二尖瓣瓣中瓣/环中瓣患者STS PROM 11%,院内死亡率7.2%,30天死亡率8.5%。

要点

  • 经导管主动脉瓣置换患者风险逐年降低,住院及1年死亡率下降。
  • TAVR术后30天起搏器植入率从8.8%升至12.0%。
  • 二尖瓣夹合患者院内死亡率2%,87%反流降至≤2级。

核心结论

  • TVT登记是监测经导管瓣膜新技术质量、患者安全与趋势的创新登记平台。

研究设计与样本

  • 基于STS/ACC TVT登记,回顾2012年至2015年12月31日所有接受商用经导管瓣膜装置的患者。

主要发现

  • 54,782例经导管主动脉瓣置换患者中,预估30天手术死亡率(STS PROM)从7%降至6%,TVT PROM从4%降至3%(均p<0.0001)。
  • 经导管主动脉瓣置换患者观察住院死亡率从5.7%降至2.9%,1年死亡率从25.8%降至21.6%。
  • 30天术后起搏器植入率从2013年8.8%升至2015年12.0%。
  • 2015年2,556例经导管二尖瓣夹合患者院内死亡率2%,87%患者二尖瓣反流降至≤2级(p<0.0001)。
  • 349例二尖瓣瓣中瓣及瓣环中瓣患者STS PROM(二尖瓣置换)11%,观察院内死亡率7.2%,30天死亡率8.5%。

关键数值与推荐

  • 经导管主动脉瓣置换患者STS PROM从7%降至6%,TVT PROM从4%降至3%(p<0.0001)。
  • 经导管主动脉瓣置换住院死亡率5.7%降至2.9%,1年死亡率25.8%降至21.6%。
  • 30天起搏器植入率2013年8.8%至2015年12.0%。
  • 二尖瓣夹合患者院内死亡率2%,87%二尖瓣反流降至≤2级(p<0.0001)。
  • 二尖瓣瓣中瓣/环中瓣患者STS PROM 11%,院内死亡率7.2%,30天死亡率8.5%。

临床怎么用

  • 可利用TVT登记数据监测经导管瓣膜治疗质量、安全性与趋势。
  • 关注TAVR术后起搏器植入率上升趋势,优化患者选择与操作。
  • 二尖瓣夹合患者可预期较好的反流改善与低院内死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Society of Thoracic Surgeons (STS)/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry captures all procedures with Food and Drug Administration-approved transcatheter valve devices performed in the United States, and is mandated as a condition of reimbursement by the Centers for Medicaid & Medicare Services. OBJECTIVES: This annual report focuses on patient characteristics, trends, and outcomes of transcatheter aortic and mitral valve catheter-based valve procedures in the United States. METHODS: We reviewed data for all patients receiving commercially approved devices from 2012 through December 31, 2015, that are entered in the TVT Registry. RESULTS: The 54,782 patients with transcatheter aortic valve replacement demonstrated decreases in expected risk of 30-day operative mortality (STS Predicted Risk of Mortality [PROM]) of 7% to 6% and transcatheter aortic valve replacement PROM (TVT PROM) of 4% to 3% (both p < 0.0001) from 2012 to 2015. Observed in-hospital mortality decreased from 5.7% to 2.9%, and 1-year mortality decreased from 25.8% to 21.6%. However, 30-day post-procedure pacemaker insertion increased from 8.8% in 2013 to 12.0% in 2015. The 2,556 patients who underwent transcatheter mitral leaflet clip in 2015 were similar to patients from 2013 to 2014, with hospital mortality of 2% and with mitral regurgitation reduced to grade ≤2 in 87% of patients (p < 0.0001). The 349 patients who underwent mitral valve-in-valve and mitral valve-in-ring procedures were high risk, with an STS PROM for mitral valve replacement of 11%. The observed hospital mortality was 7.2%, and 30-day post-procedure mortality was 8.5%. CONCLUSIONS: The TVT Registry is an innovative registry that that monitors quality, patient safety and trends for these rapidly evolving new technologies.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Grover FL, Vemulapalli S, Carroll JD, et al. 2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Ann Thorac Surg. 2016. PMID: 27955994. doi:10.1016/j.athoracsur.2016.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。